Table 7.
Changes in hematological and serum biochemical variables during the course of the study
| Factor | Probability | Regression | |
|---|---|---|---|
| WBC (×1000/µL) | Group | p=0.017 | CP1563: δWBC=0.528−0.073×Init. WBC |
| Group×Init. WBC | p<0.001 | Placebo: δWBC=1.163−0.162×Init. WBC | |
| RBC (×10,000/µL) | Group | p=0.249 | CP1563: δRBC=43.179−0.088×Init. RBC |
| Group×Init. RBC | p<0.001 | Placebo: δRBC=29.004−0.062×Init. RBC | |
| Hemoglobin (g/dL) | Group | p=0.155 | CP1563: δHb=1.005−0.070×Init. Hb |
| Group×Init. Hb | p<0.001 | Placebo: δHb=0.513−0.041×Init. Hb | |
| Hematocrit (%) | Group | p=0.106 | CP1563: δHt=3.441−0.079×Init. Ht |
| Group×Init. Ht | p<0.001 | Placebo: δHt=1.488−0.039×Init. Ht | |
| Platelet (×10,000/µL) | Group | p=0.441 | CP1563: δPLT=2.006−0.571×Init. PLT |
| Group×Init. PLT | p=0.001 | Placebo: δPLT=2.006−0.055×Init. PLT | |
| ALT (IU/L) | Group | p=0.003 | CP1563: δALT=5.373−0.181×Init. ALT |
| Group×Init. ALT | p<0.001 | Placebo: δALT=1.105−0.039×Init. ALT | |
| AST (IU/L) | Group | p<0.001 | CP1563: δAST=5.666−0.149×Init. AST |
| Group×Init. AST | p<0.001 | Placebo: δAST=–2.302+0.193×Init. AST | |
| γ-GTP (IU/L) | Group | p=0.005 | CP1563: δγGTP=−2.351+0.080×Init. γGTP |
| Group×Init. γ-GTP | p<0.001 | Placebo: δγGTP=4.093−0.128×Init. γGTP | |
| LD (IU/L) | Group | p<0.001 | CP1563: δLD=74.931−0.388×Init. LD |
| Group×Init. LD | p<0.001 | Placebo: δLD=25.641−0.138×Init. LD | |
| TP (g/dL) | Group | p=0.011 | CP1563: δTP=2.241−0.305×Init. TP |
| Group×Init. TP | p<0.001 | Placebo: δTP=1.316−0.183×Init. TP | |
| BUN (mg/dL) | Group | p=0.030 | CP1563: δBUN=1.710−0.127×Init. BUN |
| Group×Init. BUN | p<0.001 | Placebo: δBUN=3.404−0.262×Init. BUN | |
| Uric acid (mg/dL) | Group | p=0.022 | CP1563: δUA=0.822−0.144×Init.UA |
| Group×Init. UA | p<0.001 | Placebo: δUA=0.436+0.087×Init.UA | |
| Creatinine (mg/dL) | Group | p=0.428 | CP1563: δCRE=0.046−0.062×Init. CRE |
| Group×Init. CRE | p<0.001 | Placebo: δCRE=0.033−0.040×Init. CRE | |
| Bilirubin (mg/dL) | Group | p=0.426 | CP1563: δT-Bil=0.161−0.266×Init. T-Bil |
| Group×Init. T-Bil | p<0.001 | Placebo: δT-Bil=0.137−0.223×Init. T-Bil | |
| Sodium (mEq/L) | Group | p=0.283 | CP1563: δNa=46.984−0.330×Init. Na |
| Group×Init. Na | p<0.001 | Placebo: δNa=55.558−0.391×Init. Na | |
| Potassium (mEq/L) | Group | p=0.351 | CP1563: δK=1.486−0.368×Init. K |
| Group×Init. K | p<0.001 | Placebo: δK=1.297−0.321×Init. K | |
| Chloride (mEq/L) | Group | p=0.048 | CP1563: δCL=26.277−0.257×Init. Cl |
| Group×Init. Cl | p<0.001 | Placebo: δCL=37.498−0.366×Init. Cl | |
WBC, white blood cell; RBC, red blood cell; ALT, alanine aminotransferase; AST, aspartate aminotransferase; γ-GTP, γ-glutamyl transpeptidase; LD, lactate dehydrogenase; TP, total protein; BUN, blood urea nitrogen; UA, uric acid; CRE, creatinine; T-Bil, total bilirubin; Na, sodium; K, potassium; Cl, chloride.
Statistical significance was evaluated using ANCOVA for repeated measures.